Revive Therapeutics Ltd (RVVTF)
Revive Therapeutics Ltd. is a Toronto-based life sciences company listed on OTC Markets as common stock. The company focuses on researching and developing therapeutics and diagnostics aimed at infectious diseases, medical countermeasures, and rare disorders. Its pipeline includes Bucillamine, a disease-modifying anti-rheumatic drug under development for infectious diseases such as influenza and COVID-19, as well as broader applications in pandemic influenza, emerging infectious diseases, and medical countermeasure situations. Revive is also advancing psilocybin, which is in a Phase 1 clinical study for methamphetamine use disorder, and psilocin, being explored for conditions including depression, anxiety, bipolar disorder, bulimia, and anorexia nervosa.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-RVVT.F
|
$0.012
|
-39.5% Downside
|
Overvalued
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
October 28, 2026
|
-1.2x
|
-3.2x
|
—
|
7.746 M
|
9.341 M
|
0.6%
|
98.5%
|
-1,027.1
|
—
|
1.5%
|
